Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2013. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) regarding their holdings in American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
The filing details increases in ADS holdings for specific directors and connected persons following the re-investment of dividends paid on October 3, 2013. The transactions occurred at a price of $50.2130 per ADS. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a regulatory disclosure of insider share purchases.
Important Facts for Investors
- Transaction Date: Shares were purchased on October 3, 2013.
- Share Price: $50.2130 per ADS.
- Transaction Type: Re-investment of dividends paid to shareholders.
- Directors Involved: Dr M M Slaoui (932.851 ADSs), Mrs D P Connelly (484.041 ADSs), Mr W C Louv (84.312 ADSs), and Mr D E Troy (284.755 ADSs).
- Connected Persons: Dr K Slaoui (15.618 ADSs).
- Notification Date: The Company was advised of these transactions on October 9, 2013.